Drug intelligence / Profile preview

IN023

Development stage: Preclinical
Lead developer: Innorna
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

IN023 is an mRNA-based vaccine candidate being developed by InnoRNA Biotech for the prevention of Herpes Simplex Virus Type 2 (HSV-2) infection. The vaccine utilizes InnoRNA's proprietary mRNA and lipid nanoparticle (LNP) delivery technology platform, which features a diversity-oriented lipid library of over 5,000 ionizable lipids. IN023 is designed to encode viral antigens that trigger a protective immune response against HSV-2. As of early 2026, the candidate is in the IND-enabling stage of development.

Beyond the preview

Go deeper on IN023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN023.